Navigation Links
Human Pheromone Sciences Announces First Quarter Results
Date:5/15/2008

Results Impacted by Downturn in U.S. Beauty Market

SAN JOSE, Calif., May 15 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") today announced results for the first quarter ended March 31, 2008. Net revenues of $266,000 represented a 20% decrease from the revenues of $334,000 in the prior year period, and resulted in a net loss of $63,000 ($.02 per share) as compared with net income of $24,000 ($.01 per share) for the same period of 2007. At March 31, 2008, the Company reflected cash balances of $1,397,000 compared with $1,437,000 in cash at December 31, 2007, a $40,000 reduction in the quarter. There was no bank indebtedness at either period and current liabilities were the same at both periods, excluding deferred revenue changes.

According to a Company spokesperson, the results were in line with Company forecasts, and reflected the overall downturn in the U.S. Fragrance and Beauty Market sales during the period. "We had anticipated the weakness of revenues in our largest consumer product segment, and, as such, had undertaken the program to expand the markets for the use of our patented technology in other consumer product arenas. Some of the shortfall in the basic beauty area was offset by revenues received under our licensing agreement signed last year with Schwarzkopf & Henkel, in the hair care market, which was expanded in the current quarter, and recognition of revenue from our license agreement with Johnson & Johnson entered into in September 2006. It is apparent that such diversification is the way to hedge against a potential continued decline in a single market that represented our initial focus in the Fragrance and Beauty business," the spokesperson noted. As previously stated, the Company's focus in 2008 is the generation of additional licensing and supply activities, and increasing product development spending for additional compounds that have been identified and isolated and are now in advanced stages of development. "Generating additional revenues under new licensing agreements will not only grow our business, but will reduce the effect of erratic purchasing patterns by our current major licensee. With respect to the new compounds in which we are investing, we are excited about the results we have seen to date, the patent we have filed on the initial compound and the potential for other novel compounds," a Company spokesperson indicated.

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at http://www.erox.com.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-KSB for the year ended December 31, 2007, and Form 10-Q for the quarter ended March 31, 2008, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

Tables follow

HUMAN PHEROMONE SCIENCES, INC.

Condensed Balance Sheets

(Dollars in thousands)

March 31, December 31,

2008 2007

(Unaudited)

Assets

Cash and cash equivalents $ 1,397 $ 1,437

Accounts receivable 83 194

Inventories, net 45 25

Other current assets 35 40

Property and equipment, net 3 3

Total $ 1,563 $ 1,699

Liabilities and shareholders' deficit

Accounts payable $ 52 $ 28

Other current liabilities 118 141

Deferred income - current 512 518

Deferred income - non-current 469 566

Common stock 20,992 20,963

Accumulated deficit (20,580) (20,517)

Total $ 1,563 $ 1,699

HUMAN PHEROMONE SCIENCES, INC.

Condensed Statements of Operations

(Unaudited)

(Dollars in thousands, except per-share data)

Three months ended March 31,

2008 2007

Net revenues $ 266 $ 334

Cost of goods sold 81 107

Research and development 14 12

Selling, general and administrative 244 208

Income (loss) from operations (73) 7

Other income 11 18

Provision for income taxes 1 1

Net income (loss) $ (63) $ 24

Income (loss) per share, basic $ (0.02) $ 0.01

Income (loss) per share, fully diluted $ (0.02) $ 0.01

Weighted average common shares

outstanding-Basic 4,152 4,152

Weighted average common shares

outstanding-Fully diluted 4,152 4,782

Net income (loss) per share is based on the weighted average number of common shares and common equivalents outstanding during each period. Certain common stock equivalents are excluded when their effect would be anti- dilutive.


'/>"/>
SOURCE Human Pheromone Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers find first conclusive evidence of Alzheimers-like brain tangles in nonhuman primates
2. Vancouver researchers discover missing link between TB bacteria and humans
3. The California Dental Association Foundation Presents Inaugural Humanitarian Award to USC Mobile Dental Clinics Champion Charles M. Goldstein, DDS, MPH
4. Wyle Targets New Customers for Expanded Human Health and Performance Capabilities and Services
5. Human aging gene found in flies
6. Stroke Survivors Walk Better With Human Help
7. Virus mimics human protein to hijack cell division machinery
8. Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors
9. St. Jude finds dancing hair cells are key to humans acute hearing
10. Six Youths Secure Top Spots in American Humane Kind Kid Contest
11. AVMA Passes New Policy to Encourage Humane Treatment of Captive Elephants, Appropriate Use of Training Tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: